Moderna getting ripe: CMP 28While short-term indicators show some bullish signs, the medium- and long-term trends remain bearish.
The stock might remain range-bound for a couple of weeks before any uptrend, which will only be confirmed once it breaks the parallel line before making a fresh upmove. Also, $27.5 can be taken as
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−8.72 USD
−3.56 B USD
3.24 B USD
342.49 M
About Moderna, Inc.
Sector
Industry
CEO
Stéphane Bancel
Website
Headquarters
Cambridge
Founded
2010
FIGI
BBG003PHHZT1
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
Moderna - Long
Moderna is showing signs of recovery. Has made a base in the weekly and daily charts as marked by sky blue and white horizontal lines.
Immediate target $128.
However, there are another 3 and half days left for the end of the week. Smart recovery is on the cards, next week.
I am not a register
Sunday Prep 9/5 - $MRNA Looking good for a move back to ATHThe setup is there to take this name back to ATHs. Technically needs over 418.44 to confirm the long trigger, but don’t think that’s going to be a problem if the momentum continues.
Will need to see some retests of key levels hold before being interested. First area of interest would be the rece
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where MRNA is featured.
Related stocks
Frequently Asked Questions
The current price of MRNA is 25.55 USD — it has decreased by −0.88% in the past 24 hours. Watch Moderna, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Moderna, Inc. stocks are traded under the ticker MRNA.
MRNA stock has fallen by −7.50% compared to the previous week, the month change is a 7.96% rise, over the last year Moderna, Inc. has showed a −81.51% decrease.
We've gathered analysts' opinions on Moderna, Inc. future price: according to them, MRNA price has a max estimate of 198.00 USD and a min estimate of 20.00 USD. Watch MRNA chart and read a more detailed Moderna, Inc. stock forecast: see what analysts think of Moderna, Inc. and suggest that you do with its stocks.
MRNA reached its all-time high on Aug 10, 2021 with the price of 497.49 USD, and its all-time low was 11.54 USD and was reached on Aug 7, 2019. View more price dynamics on MRNA chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
MRNA stock is 3.54% volatile and has beta coefficient of 0.95. Track Moderna, Inc. stock price on the chart and check out the list of the most volatile stocks — is Moderna, Inc. there?
Today Moderna, Inc. has the market capitalization of 10.06 B, it has increased by 2.55% over the last week.
Yes, you can track Moderna, Inc. financials in yearly and quarterly reports right on TradingView.
Moderna, Inc. is going to release the next earnings report on Jul 31, 2025. Keep track of upcoming events with our Earnings Calendar.
MRNA earnings for the last quarter are −2.52 USD per share, whereas the estimation was −3.12 USD resulting in a 19.13% surprise. The estimated earnings for the next quarter are −2.96 USD per share. See more details about Moderna, Inc. earnings.
Moderna, Inc. revenue for the last quarter amounts to 108.00 M USD, despite the estimated figure of 106.18 M USD. In the next quarter, revenue is expected to reach 116.35 M USD.
MRNA net income for the last quarter is −971.00 M USD, while the quarter before that showed −1.12 B USD of net income which accounts for 13.30% change. Track more Moderna, Inc. financial stats to get the full picture.
No, MRNA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jun 18, 2025, the company has 5.8 K employees. See our rating of the largest employees — is Moderna, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Moderna, Inc. EBITDA is −3.54 B USD, and current EBITDA margin is −116.07%. See more stats in Moderna, Inc. financial statements.
Like other stocks, MRNA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Moderna, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Moderna, Inc. technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Moderna, Inc. stock shows the sell signal. See more of Moderna, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.